Compare ALLT & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLT | SLDB |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 519.6M | 498.6M |
| IPO Year | 2006 | 2017 |
| Metric | ALLT | SLDB |
|---|---|---|
| Price | $7.01 | $7.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $12.25 | ★ $14.70 |
| AVG Volume (30 Days) | 672.8K | ★ 1.2M |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,094,000.00 |
| Revenue This Year | $14.86 | N/A |
| Revenue Next Year | $12.10 | N/A |
| P/E Ratio | $469.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.37 | $2.45 |
| 52 Week High | $11.92 | $7.37 |
| Indicator | ALLT | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 68.05 |
| Support Level | $6.20 | $5.08 |
| Resistance Level | $8.20 | N/A |
| Average True Range (ATR) | 0.59 | 0.45 |
| MACD | -0.17 | 0.11 |
| Stochastic Oscillator | 19.10 | 95.35 |
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.